Methoxamine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Methoxamine is an α₁–adrenergic receptor agonist,^[1] similar in structure to phenylephrine and 2,5-DMA. It was developed by Burroughs-Wellcome in the 1940s.^[2] The drug induces vasoconstriction of skin and splanchnic blood vessels, thereby increasing peripheral vascular resistance and raising mean arterial blood pressure. Because of its hypertensive effects, it may evoke a compensatory reflex bradycardia via the baroreceptors.

References

↑ Pazdernik, Thomas L.; Kerecsen, Laszlo (2007) [2003]. “5”. In Goljan, Edward F. Pharmacology (Paperback)|format= requires |url= (help). Rapid Review (Second ed.). Philadelphia, PA: Mosby-Elsevier. p. 39. ISBN 978-0-323-04550-6. |access-date= requires |url= (help)
↑ US Patent 2359707 – DIMETHOXYPHENYL beta-HYDROXY ISOPROPYLAMINE

Template:Stimulants Template:Cardiac stimulants excluding cardiac glycosides Template:Phenethylamines

[1] Pazdernik, Thomas L.; Kerecsen, Laszlo (2007) [2003]. “5”. In Goljan, Edward F. Pharmacology (Paperback)|format= requires |url= (help). Rapid Review (Second ed.). Philadelphia, PA: Mosby-Elsevier. p. 39. ISBN 978-0-323-04550-6. |access-date= requires |url= (help)

[2] US Patent 2359707 – DIMETHOXYPHENYL beta-HYDROXY ISOPROPYLAMINE

[1]

[2]

Methoxamine

Overview

See Also

References